Answers are grounded in this paper and cite their sources.
INTRODUCTION: Longstanding, severe alopecia areata (AA) often resists standard treatments, creating a need for effective alternatives. Janus kinase inhibitors, such as baricitinib, have emerged as potential therapies for chronic AA. OBJECTIVES: To assess the efficacy and safety of oral baricitinib 4 mg daily in patients with persistent AA unresponsive to conventional treatments for over 5 years. METHODS: One hundred ten patients received baricitinib for 52 weeks. Efficacy was measured by changes in the Severity of Alopecia Tool (SALT) score, eyebrow and eyelash Clinician-Reported Outcome (ClinRO) scores, and Dermatology Life Quality Index (DLQI). Adverse events (AEs) were monitored throughout. RESULTS: At week 52, the mean SALT score improved from 75.3 to 34.8, with 38.2% achieving SALT <20, indicating significant scalp hair regrowth. Eyebrow and eyelash ClinRO scores improved, and DLQI decreased by 10.3 points. Most AEs were mild (upper respiratory tract infections and nasopharyngitis); no serious events or treatment discontinuations occurred. CONCLUSION: Baricitinib provided meaningful hair regrowth and improved quality of life in patients with persistent AA who failed previous therapies, with a favorable safety profile. These findings support consideration of baricitinib as a therapeutic option for refractory AA, though further long-term studies are warranted.
No takes yet. Share an insight, caveat, or question.
Albalat et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: